These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 8183238)
1. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor. Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238 [TBL] [Abstract][Full Text] [Related]
2. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179. Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190 [TBL] [Abstract][Full Text] [Related]
3. A new probe for affinity labelling pancreatic cholecystokinin receptor with minor modification of its structure. Fourmy D; Lopez P; Poirot S; Jimenez J; Dufresne M; Moroder L; Powers SP; Vaysse N Eur J Biochem; 1989 Nov; 185(2):397-403. PubMed ID: 2583188 [TBL] [Abstract][Full Text] [Related]
4. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors. Zhou W; Povoski SP; Bell RH J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864 [TBL] [Abstract][Full Text] [Related]
5. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin. Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537 [TBL] [Abstract][Full Text] [Related]
6. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely. Hadac EM; Ji Z; Pinon DI; Henne RM; Lybrand TP; Miller LJ J Med Chem; 1999 Jun; 42(12):2105-11. PubMed ID: 10377216 [TBL] [Abstract][Full Text] [Related]
7. Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas. Povoski SP; Zhou W; Longnecker DS; Bell RH Oncol Res; 1994; 6(9):411-7. PubMed ID: 7703527 [TBL] [Abstract][Full Text] [Related]
8. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33). Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of A- and B-subtypes of cholecystokinin/gastrin receptors in the developing calf pancreas. Le Meuth V; Philouze-Rome V; Le Huerou-Luron I; Formal M; Vaysse N; Gespach C; Guilloteau P; Fourmy D Endocrinology; 1993 Sep; 133(3):1182-91. PubMed ID: 8365360 [TBL] [Abstract][Full Text] [Related]
11. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization. Zhou W; Povoski SP; Longnecker DS; Bell RH Cancer Res; 1992 Dec; 52(24):6905-11. PubMed ID: 1458479 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696 [TBL] [Abstract][Full Text] [Related]
13. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Chang RS; Lotti VJ; Chen TB; Kunkel KA Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478 [TBL] [Abstract][Full Text] [Related]
15. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. Dong M; Liu G; Pinon DI; Miller LJ Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403 [TBL] [Abstract][Full Text] [Related]
16. Affinity labeling of a novel cholecystokinin-binding protein in rat pancreatic plasmalemma using new short probes for the receptor. Pearson RK; Miller LJ J Biol Chem; 1987 Jan; 262(2):869-76. PubMed ID: 3805011 [TBL] [Abstract][Full Text] [Related]
17. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor. Yule DI; Williams JA Peptides; 1994; 15(6):1045-51. PubMed ID: 7527529 [TBL] [Abstract][Full Text] [Related]